Patent 11866431 was granted and assigned to Vivace Therapeutics on January, 2024 by the United States Patent and Trademark Office.
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.